Psychotropic Drugs May Cause Weight Gain By Altering Your Genes: Study

Side effects of certain psychotropic drugs used to treat depression, bipolar disorder and other conditions may cause changes to an individual’s genes that increases the risk of weight gain and other health problems, according to the findings of new research.

In a study published last month in the medical journal Clinical Epigenetics, a team of Swiss researchers indicate that psychotropic drugs like clozapine and Risperdal may result in serious weight gain, placing users at risk of obesity.

The CREB-regulated transcription coactivator 1 (CRTC1) gene plays a major role in regulating energy in the body and other epigenetic mechanisms. For that reason, researchers focused on changes to this gene during the new study.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

A total of 78 patients were given psychotropic drugs known to induce metabolic disturbances. Patients had their weight and other metabolic parameters monitored regularly and methylation levels in the CRTC1 gene was assessed before and after one month of psychotropic treatment.

Half the patients received psychotropic therapies with a moderate influence on weight gain including Lithium, Remeron, Seroquel, and Risperdal.One-third of patients were given medications with a high risk of inducing weight gain, including Clozapine, Zyprexa, and Depakote.

The data indicated psychotropic drugs lead to early weight gain in people with psychiatric disorders because of altered expression of the CRTC1 gene.

Patients included in the study had bipolar disorder, schizophrenia, and major depressive disorder. The study indicated they are at risk of developing metabolic diseases, such as obesity or high cholesterol, if they take psychotropic drugs.

Taking any of the psychotropic drugs altered methylation levels significantly at three locations in the CRTC1 gene of patients with early weight gain compared to patients with no weight gain.

Researchers determined the weight gain was linked to people carrying a mutation in a particular methylation site of the CRTC1 gene, the cg12034943 site. They said the weight gain is partially due to appetite-stimulating side effects of psychotropic medications such as antipsychotics, mood stabilizers, and some antidepressants.

However, the drugs also lead to changes directly in the genes of patients because the gene is also associated with body fat percentage.

“These findings give new insights on psychotropic-induced weight gain and underline the need of future larger prospective epigenetic studies to better understand the complex pathways involved in psychotropic-induced metabolic side effects,” wrote study authors.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

An increasing number of Ozempic and Mounjaro users are reporting sudden, irreversible vision loss from NAION side effects, prompting new lawsuits and a federal push to consolidate blindness claims into a dedicated multidistrict litigation.
Cartiva is urging federal judges to reject consolidation of toe-implant lawsuits, arguing that an MDL would interfere with individual claim resolutions that the company says are already being handled efficiently outside of court.
The first Covidien Symbotex mesh bellwether has been restored to the 2026 trial calendar, signaling renewed momentum in a litigation where more than 2,000 similar claims are still awaiting resolution.